Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin

The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use